Two measures being developed in Washington could help offset the burden imposed by a requirement for extensive cardiovascular risk assessment of drugs to treat obesity. Both could shift the paradigm away from developing agents for the broader population.

In the first, FDA is working with academics to define new endpoints and identify narrower groups of patients most likely to benefit from weight loss treatments.